Neuroscientific Biopharmaceuticals (ASX:NSB) share price jumps 9% before trading halt

It's been an interesting day on the ASX for the Australian biotech company. Here are the details

| More on:
health worker wearing personal protective equipment and gesturing stop with her hands

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Neuroscientific Biopharmaceuticals Ltd (ASX: NSB) share price jumped higher this morning before becoming subject to a trading halt at lunchtime.

Before the pause in trading, the Australian biotech company's shares were exchanging hands at 31.5 cents apiece, an 8.6% leap from the open. The share price gain came after an update was released to the market prior to the opening bell.

What did Neuroscientific announce today?

Neuroscientific shares jumped on Thursday as the company provided an update on its EmtinB label.

According to Neuroscientific, "EmtinB is currently being developed as a treatment for neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve".

The announcement said EmtinB was shown to be effective in reducing "important biomarkers" associated with severe COVID-19. The study demonstrated Neuroscientific's label was effective in reducing these biomarkers by "more than 50%", versus controls.

As such, this indicates a "strong therapeutic potential" for EmtinB, "in preventing severe immune responses" from COVID-19.

Neuroscientific's hypothesis in examining EmtinB in COVID-19 was to address the "cytokine storm" that occurs with an aggressive inflammatory response in COVID-19 infection.

For example, this "storm" results in a cascade of uncontrolled inflammation in the body, which decreases a person's lung function. A rise in the incidence of these events has been purported with COVID-19, thereby leading Neuroscientific to conduct its trial.

The results obtained suggest EmtinB "is safe to administer in future work", and are an important milestone for the company.

Why are Neuroscientific shares in a trading halt?

Shares paused trading just after midday on Thursday, with the company stating it was working to "finalise an announcement detailing further information in regard to the results from pulmonary studies as announced today".

The halt will remain in place until Monday 23 August, or until the announcement is released to the market.

Neuroscientific share price snapshot

The Neuroscientific Biopharmaceuticals share price has posted a year-to-date return of 26%, extending the previous 12 months' climb of 31%.

These returns have both outpaced the S&P/ASX 200 Index (ASX: XJO)'s gain of around 25% over the last year.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Here are the top 10 ASX 200 shares today

The ASX 200 made it three-for-three losses in a row this Wednesday.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Broker Notes

Guess which ASX 200 stock was just upgraded to a buy rating

Why did the broker just turn bullish? Let's find out.

Read more »

Man on a laptop thinking.
Share Market News

Why is the ASX 200 having such a bad day on Wednesday?

Several factors are at play.

Read more »

Four young friends on a road trip smile and laugh as they sit on roof of their car.
ETFs

4 popular ASX tech ETFs smashing new all-time highs today

Do you own any of these lucky ETFs?

Read more »

A young woman wearing overalls and a yellow t-shirt kicks one leg in the air showing excitement over the latest ASX 200 shares to hit 52-week highs
Share Gainers

Why Brickworks, James Hardie, Megaport, and OFX shares are charging higher today

These shares are having a good time on hump day. But why?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Fallers

Why Insignia, Light & Wonder, Mineral Resources, and Nuix shares are sinking today

These shares are having a difficult time on hump day. But why?

Read more »

A view from the track behind a runner in the starting block.
Opinions

3 beginner-friendly ASX shares perfect for Aussie investors starting out in November

Here’s why I like the look of these ASX shares for beginners.

Read more »

A group of business people pump the air and cheer.
Mergers & Acquisitions

This ASX small-cap stock is exploding 75% on takeover news!

The takeover premium is large.

Read more »